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Background: Multiple stimuli converge in cardiopulmonary bypass to
create a tremendous prothrombotic stimulus. The ideal anticoagulant
for cardiopulmonary bypass should selectively target only the intravas-
cular stimuli, thereby eliminating pathologic clotting in the bypass cir-
cuit while preserving hemostasis in the thoracic cavity. We propose the
inhibition of factor IX as such a targeted anticoagulant strategy.
Methods: We prepared an inhibitor of activated factor IX and applied it
to a primate model of cardiopulmonary bypass to confirm the anticoag-
ulant efficacy of activated factor IX in this setting and to assess more
subtle markers of thrombin generation, macrophage procoagulant
activity, and cellular tissue factor expression. Seven baboons that
received activated factor IX (460 m g/kg) and 7 that received heparin (300
IU/kg) and protamine underwent cardiopulmonary bypass for 90 min-
utes and were followed after the operation for 3 hours. Results: Analysis
of plasma factor IX activity demonstrated adequate inhibition (<20%)
of factor IX throughout cardiopulmonary bypass. Activated factor
IX–treated baboons demonstrated similar circuit patency to heparin-
treated baboons but had significantly diminished intraoperative blood
loss. Preservation of extravascular hemostasis was further demonstrat-
ed in activated factor IX–treated animals by (1) significantly increased
levels of thrombin-antithrombin III complex and prothrombin activa-
tion peptide (F1+2) without intravascular thrombosis, (2) significantly
greater macrophage procoagulant activity in pericardial-derived mono-
cytes, and (3) immunohistochemical evidence of tissue factor expression
in pericardial mesothelial cells and macrophages. Conclusions:
Anticoagulation with activated factor IX allows for intravascular anti-
coagulation with maintenance of extravascular hemostasis. These find-
ings suggest activated factor IX as an agent that not only exemplifies a
targeted approach to selective anticoagulation in cardiac surgery but
also further characterizes the procoagulant milieu during cardiopul-
monary bypass. (J Thorac Cardiovasc Surg 1998;116:860-9)
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A lthough the mechanism by which coagulation isactivated in the setting of cardiopulmonary bypass
(CPB) remains to be elucidated fully, multiple factors
are thought to converge that comprise a tremendous,
complex prothrombotic stimulus.1-4 The contributions
of 3 separate procoagulant stimuli have been most
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often implicated in this process. First, an obvious role
for the intrinsic system has been delineated because of
the contact of blood with the bypass circuit.5,6
Activated monocytes have also been demonstrated to
adhere to the circuit where they express low levels of
tissue factor (TF), thereby propagating the procoagu-
lant response.7 Finally, a role for the extrinsic system
has been suggested with contributions from high levels
of TF in the surgical wound.8
Separating the individual contributions of these pro-
coagulant stimuli constitutes the basis for a targeted
approach to anticoagulation during CPB. In this setting,
the ideal anticoagulant strategy seeks to eliminate
pathologic clotting in the bypass circuit while preserv-
ing hemostasis in the thoracic cavity. Heparin, the tra-
ditional antithrombotic agent used in CPB, blocks all 3
implicated procoagulant stimuli through its multiple
sites of action in the coagulation cascade, thereby
allowing successful passage of blood throughout the
extracorporeal circulation only at the expense of unin-
hibited bleeding in the surgical wound.9-12 In contrast,
blockade of factor IX represents a more directed anti-
coagulant approach, inhibiting only 2 of these procoag-
ulant mechanisms.
Factor IX is activated both by stimulation of the
intrinsic system13-14 and by low amounts of TF.15,16
Inhibition of factor IX will therefore not only limit
thrombin generation within the bypass circuit caused
by blood contact but also impede the procoagulant
activity of adherent monocytes. Blockade of factor IX
will not, however, interfere with the extrinsic system
and clot formation in the surgical wound, where high
levels of TF bypass factor IX and directly activate fac-
tor X (Fig 1).17
We prepared a novel inhibitor of activated factor IX
(IXai) and have used this agent as an anticoagulant in a
canine model of CPB18 in which we demonstrated the
feasibility of this anticoagulant strategy. In the current
study, we have extended this evaluation to a primate
model to confirm the anticoagulant efficacy of IXai
with assessment of bypass circuit patency and surgical
hemostasis and to assess more subtle markers of throm-
bin generation, macrophage procoagulant activity, and
cellular TF expression. These findings suggest IXai as
a novel agent that not only exemplifies a targeted
approach to selective anticoagulation in cardiac surgery
but also further characterizes the procoagulant milieu
during CPB.
Materials and methods
IXai
Preparation and purification of factor IXa/IXai. IXai was
prepared from factor IX complex (Proplex) by enzymatic
modification of the active-site residues serine 376 and histi-
dine 221 of factor IX, which were acetylated and alkylated,
respectively, with dansyl-glu-gly-arg chloromethylketone
(Calbiochem, San Diego, Calif).18-22 IXai acts as a competi-
tive inhibitor of the assembly of factor IXa in the intrinsic
factor X activation complex. In this study, IXai was used at a
previously established antithrombotic dose of 460 m g/kg in
baboon CPB.18
Primate model
CPB in baboons. Fourteen baboons (13-16 kg) underwent
CPB for 90 minutes after anesthesia was induced with isoflu-
rane and endotracheal intubation. After median sternotomy,
the heart was suspended in a pericardial cradle. Animals were
randomized to receive either IXai (460 m g/kg; n = 7) or
heparin (300 IU/kg; n = 7), which was infused as a bolus dose
after which CPB was established with cannulation of the right
atrial appendage and ascending aorta (70 mL/kg/min; 32°C;
mean arterial pressure, 55 to 70 mm Hg). CPB was maintained
for 90 minutes with a roller head pump (Stockert Shiley
Instruments, Munich, West Germany) primed with type-
matched baboon blood, lactated Ringer’s solution, and a Cobe
membrane lung oxygenator (Cobe Cardiovascular, Arvada,
Colo) with sterile Tygon tubing (Norton Plastics, Akron,
Ohio). The baboons were weaned and decannulated. In
baboons treated with heparin, protamine (1 mg/100 IU
heparin) was administered intravenously. Animals were then
observed for up to 3 hours to obtain blood samples and mea-
sure extent of blood loss. At 30-minute intervals after bypass,
blood that pooled in the pericardial and pleural spaces was
suctioned, and the amount was quantitated and recorded.
Continuous hemodynamic measurements were made and
recorded before, during, and up to 3 hours after institution of
CPB.
All animals received humane care in compliance with the
“Principles of Laboratory Animal Care” formulated by the
Fig 1. Divergent role of factor IX in the procoagulant
response in the setting of low (intrinsic system) or high
(extrinsic system) levels of TF.
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National Society for Medical Research and the “Guide for the
Care and Use of Laboratory Animals” prepared by the
National Academy of Sciences and published by the National
Institutes of Health (NIH publication 85-23, revised 1985).
This study was approved by the Columbia University
Institutional Animal Review Committee and was conducted
according to policies set forth by Columbia University.
Efficacy of anticoagulation
Analysis of blood samples. Routine hematologic analysis
was performed before the initiation of CPB, every 30 minutes
during CPB, and after the operation to determine levels of
hemoglobin and hematocrit (analyzed on an ISTAT arterial
blood analyzer [I-STAT Corporation, Princeton, NJ]), pro-
thrombin time, activated partial thromboplastin time (mea-
sured on the ST4 Bio clot detection system with reagents pro-
vided by the manufacturer [Diagnostica Stago, Asnieres,
France]), and activated clotting time (measured on a
Hemochron model 801 ACT machine [International
Technidyne Corp, Edison, NJ] with Flip-Top Celite ACT
tubes [Celite Corporation, Quincy, Mass]).
Assessment of IXai antithrombotic effect. The antithrom-
botic activity of factor IXai in plasma was assessed by the
testing of peripheral plasma with an assay of factor IX activ-
ity as determined on the ST4 Bio clot detection system
(Diagnostica Stago) with factor IX–deficient plasma, a partial
thromboplastin time reagent, and 0.025 mmol/L calcium
chloride (Diagnostica Stago) in the manner described by the
manufacturer. A standard curve for factor IX activity was
established with factor control plasma (Diagnostica Stago).
Data are expressed both as an absolute value in seconds and
as a percent of normal factor IX activity.
Assessment of fibrin deposition in the CPB tubing and fil-
ters. At the end of CPB, the tubing and filters were removed
and subjected to qualitative analysis by scanning electron
microscopy as previously described.23
Assessment of extrinsic hemostasis. To establish the effects
of IXai on bleeding tendency outside the operative field, a
standardized incisional model in the abdomen was used, as
described previously.24 A uniform 1-cm deep, 5-cm long
abdominal wall incision was made before the operation, dur-
ing CPB, and 3 hours after the operation. A preweighed gauze
pad was inserted for 5 minutes. At the end of that time, the
gauze was removed and weighed to quantitate the blood loss. 
Thrombin generation
Assessment of peripheral markers of thrombin generation.
Blood was obtained from the peripheral arterial catheter at
baseline, after infusion of IXai, and at designated times on
CPB (0.5 hour, 1 hour, and 1.5 hours). Blood was also
obtained from the pericardial cavity, drawn from the CPB cir-
cuit after infusion of IXai and at the times mentioned earlier
during CPB. Blood was drawn into sodium citrate (3.8%; 9:1
vol/vol), and platelet-poor plasma was separated and assayed
by enzyme-linked immunosorbent assay (ELISA) for throm-
bin-antithrombin III complex (TAT) and prothrombin activa-
tion peptide (F1+2) as instructed by the manufacturer (Behring
Diagnostics, Inc, Westwood, Mass). The limits of detection in
these assays were as follows: TAT, 2 m g/L; F1+2, 0.04 nmol/L.
Macrophage procoagulant activity 
Isolation of mononuclear cells and analysis of procoagu-
lant activity. Immediately before the animals were killed,
blood (~18 mL) was retrieved from the arterial catheter,
bypass circuit, and pericardial cavity from 6 animals (3 IXai,
3 heparin). In addition, adherent mononuclear cells were har-
vested from the arterial oxygenator when the surface was
washed in a solution containing EDTA (0.01 mol/L), NaCl
(0.150 mol/L), and HEPES (0.01 mol/L). Cells were then
concentrated by centrifugation (900g for 20 minutes); the
resulting pellet was resuspended in Hanks’ balanced salt solu-
tion (Gibco, Grand Island, NY) containing HEPES (0.025
mol/L; pH 7.4). In all cases, samples containing mononuclear
cells were then layered onto a histopaque gradient (1077;
Sigma Chemical Co, St Louis, Mo) for isolation of mononu-
clear cell fraction as previously described.25 The resultant
mononuclear cells (2.5 · 107 cells/assay) were placed into
24-well tissue culture plates (Corning, Inc, Corning, NY) and
incubated alone or in the presence of lipopolysaccharide (10
m g/mL) from Escherichia coli serotype 026:B6 (Sigma
Chemical Co) in Hanks’ buffered salt solution containing
human plasma (20%) for 2 hours at 37°C. Analysis of TF
activity was performed as previously described.8,26,27 In brief,
procoagulant activity was performed with a 1-step recalcifi-
cation time procedure. Mononuclear cells were lysed by the
addition of octyl-b -glucopyranoside (15 mmol/L; Calbio-
chem) in Hanks’ balanced salt solution containing HEPES
(0.025 mol/L). The resulting suspension was incubated with
pooled normal plasma at 37°C for 3 minutes, after which time
CaCl2 (0.025 mol/L) was added; the clotting time was deter-
mined by visual detection of clot formation. Each sample was
run in triplicate, and serial dilutions of purified human TF
(American Diagnostica, Greenwich, Conn) were used to gen-
erate a standard curve.
Cellular TF expression
Immunohistochemistry. Pericardial tissue was harvested at
initiation of CPB and after 90 minutes and placed in formalin
(10%). Paraffin sections (5-m m thick) were prepared and
stained either with anti-TF immunoglobulin G (IgG) (1:100
dilution; American Diagnostica) or nonimmune IgG (mouse)
according to the manufacturer’s instructions.
Statistical analysis. Data are expressed as the mean ± the SE
in the text and as mean ± SD in the tables and figures, as indi-
cated. Serial data from each group were evaluated by the repeat-
ed measures analysis of variance and then by paired t test.
Results
Efficacy of anticoagulation
Analysis of blood samples. The use of IXai as an anti-
coagulant in CPB did not adversely affect routinely
measured hematologic values. Compared with heparin,
no untoward effects were observed at 90 minutes of
CPB on either white blood cell count (H, 4.7 ± 1.1 ·
103, versus IXai, 5.2 ± 0.9 · 103; P = .3 ), hematocrit
values (H, 17.2% ± 2.1%, versus IXai, 18.9% ± 2.4%;
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P = .4), or platelet counts (H, 1.5 ± 0.2 · 109/L, versus
IXai, 1.9 ± 0.6 · 109/L; P = .3); both groups demon-
strated similar decreases in these values consistent with
hemodilution. Standard parameters of coagulation, used
to assess and quantitate antithrombotic effect in the
peripheral plasma, showed that, compared with heparin-
treated baboons, baboons treated with IXai demonstrat-
ed significantly decreased rises in both prothrombin
time and activated partial thromboplastin time.
Similarly, compared with heparin-treated baboons in
which activated clotting time (ACT) was maintained for
more than 480 seconds throughout CPB, doses of IXai
that effectively prevented thrombosis within the extra-
corporeal circulation were associated with ACTs that
did not differ from baseline (Table I).
Assessment of IXai antithrombotic effect. Using an
assay assessing in vivo factor IX activity, we deter-
mined that normal factor IX activity in baboons is
approximately 31 seconds (>100% factor IX activity).
At effective antithrombotic doses of IXai, the factor IX
activity (69 ± 2.1 seconds) represented less than 35%
factor IX activity and was maintained at that level
through 90 minutes of CPB (Table I). Assessment of
factor IX activity beyond CPB revealed that levels
slowly rose by 1 hour after CPB (57 ± 3.2 seconds;
66% activity), and further increased by 3 hours after
initiation of CPB (52 ± 3.1 seconds; 86% activity). In
primate-clearance studies, IXai demonstrates an in vivo
half life of approximately 90 minutes with factor IX
activity levels returning to more than 100% by 4 hours
after administration. Factor IX activity in heparin-treat-
ed animals was less than 6% throughout CPB and
returned to more than 100% activity after heparin
reversal with protamine.
Assessment of fibrin deposition in the CPB tubing
and filters. Compared with baboons receiving
heparin/protamine, baboons treated with IXai demon-
strated no evidence of increased pressures within the
CPB circuitry. Consistent with these findings, scanning
electron microscopy of the arterial filters retrieved at
Table I. Analysis of coagulation variables and factor IX activity in baboons undergoing CPB
Factor IX activity
ACT (sec) PT (sec) PTT (sec) Seconds Percent
Heparin
Baseline 136 ± 17 15.6 ± 0.3 36.7 ± 2.3 31 ± 1.1 >100
CPB 570 ± 87 17 ± 0.7 >180 >180 <6
90 min CPB 780 ± 220 16.9 ± 0.6 >180 >180 <6
60 min after CPB 150 ± 18 15 ± 0.8 54 ± 3.2 56 ± 2.1 56
120 min after PCB 143 ± 17 15.6 ± 0.7 52 ± 4.6 50 ± 1.3 76
180 min after CPB 135 ± 22 16 ± 0.8 46 ± 5.2 48 ± 2.4 96
IXai
Baseline 117 ± 7 15 ± 0.6 38 ± 1.9 31 ± 2.3 >100
CPB 154 ± 17 16 ± 0.6 67 ± 2.3 69 ± 2.1 32
90 min CPB 165 ± 23 16.5 ± 0.4 74 ± 3.4 76 ± 2.1 19
60 min after CPB 143 ± 35 17 ± 0.6 56 ± 2.3 57 ± 3.2 66
120 min after PCB 134 ± 22 16.6 ± 0.7 54 ± 4.1 55 ± 3.1 73
180 min after CPB 120 ± 18 15.8 ± 0.7 49 ± 5.2 52 ± 3.1 86
P < .05, comparing heparin to IXai for CPB and 90-minute values: ACT, Activated clotting time; PT, prothrombin time; PTT, (PT), partial thromboplastin time.
Table II. Thoracic cavity blood loss in baboons
undergoing CPB
Incisional wound model (g)
Total blood 
loss (mL) Baseline CPB After CPB
Heparin 1250 ± 115 0.9 ± 0.2 5.9 ± 0.7 1.4 ± 0.4
IXai 480 ± 30* 0.8 ± 0.4 1.1 ± 0.5* 0.9 ± 0.3
*P < .05 by ANOVA, comparing IXai versus heparin.
Table III. Analysis of macrophage procoagulant
activity (PCA) in baboons undergoing CPB with IXai
Activity (%)
(–)LPS (+)LPS
Intravascular space
Peripheral blood 0 21 ± 3
Arterial filter 0 20 ± 2
CPB circuit 0 22 ± 3
Extravascular space
Pericardial blood 56 ± 4* 99 ± 1†
LPS, Lipopolysaccharide.
*P < .05. 
†P < .001 by ANOVA, comparing extravascular versus intravascular values. 
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the end of CPB revealed no evidence of increased clot
formation in baboons treated with effective antithrom-
botic doses of IXai (460 m g/kg) compared with
baboons treated with heparin (Fig 2). 
Assessment of extrinsic hemostasis. Baboons under-
going CPB with IXai demonstrated significantly
diminished blood loss at the end of CPB and during the
postoperative period, when compared with baboons
receiving heparin/protamine (480 ± 30 mL versus 1250
± 115 mL; P < .05, respectively; Table II). Importantly,
at effective antithrombotic doses of IXai, clot forma-
tion was noted along the cut surface of the sternum and
surgical tissue planes throughout the thoracic cavity.
Furthermore, evaluation of the effects of IXai on bleed-
ing tendency outside the operative field with a stan-
dardized incisional abdominal wound model demon-
strated that, at effective antithrombotic doses of IXai,
there was no evidence of an enhanced bleeding tenden-
cy either during CPB or after the operation compared
with baseline (Table II). In contrast, significantly
increased bleeding was observed after infusion of
heparin during CPB, which returned to baseline after
heparin reversal with protamine.
Thrombin generation
Assessment of peripheral markers of thrombin gener-
ation. Evaluation of thrombin generation in peripheral
plasma showed that, compared with heparin-treated
animals, animals treated with IXai demonstrated sig-
nificantly increased levels of TAT and prothrombin
activation peptide (F1+2), with peak levels occurring on
CPB, although levels of both markers rose progressively
in the postoperative period (Fig 3). (Both TAT and F1+2
are sensitive/specific markers of the effect of factor Xa
on prothrombin.) Evaluation of TAT and F1+2 in peri-
Fig 2. Scanning electron microscopy of the CPB filters. CPB performed in animals treated with factor IXai was
associated with comparable clinically inapparent fibrin deposition on arterial filters (left panel) when compared
with animals treated with heparin (right panel). Original magnification is indicated.
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cardial blood after 90 minutes of CPB demonstrated an
almost 4-fold increased rise when compared with con-
currently obtained peripheral blood samples in IXai-
treated animals (TAT, 423 ± 47 m g/L versus 157 ± 78
m g/L; P < .002 ; F1+2, 26 ± 8 nmol/L versus 6 ± 2
nmol/L; P < .001).
Macrophage procoagulant activity 
Isolation of mononuclear cells and analysis of proco-
agulant activity. Consistent with the hypothesis that acti-
vation of the extrinsic pathway largely occurs in the sur-
gical wound, retrieval of monocytes from intravascular
space (peripheral blood, arterial filter, and CPB pump)
during the procedure revealed no demonstrable TF activ-
ity (Table III). In contrast, monocytes isolated from extra-
vascular space (pericardial blood) manifested significant-
ly greater procoagulant activity compared with those in
the circuit/periphery (P < .05). Lipopolysaccharide, a
known inducer of monocyte procoagulant activity, was
used as a positive control in these assays.
Cellular TF expression
Immunohistochemistry. Further evidence for en-
hanced TF activity in the surgical wound was demon-
strated by immunohistochemical examination of the
pericardium during CPB (approximately 1 hour after
sternotomy and pericardial dissection). Striking TF
expression in the pericardial mesothelial cells and in
the vasculature and macrophages that pervade pericar-
dial tissue (Fig 4, A through D) was demonstrated with
anti-TF IgG. In contrast, staining of an adjacent section
with nonimmune IgG was negative (Fig 4, D).
Discussion 
The relative contributions of the different coagulation
pathways in the potent, prothrombotic environment of
CPB have not yet been defined.1-4 The intrinsic path-
way has been implicated most often as the result of
contact of blood with the extensive foreign surface of
the extracorporeal circuit. In support of this, reduced
levels of factor XII, and increased levels of its activated
form (XIIa), have been demonstrated during CPB.27,28
Furthermore, peripheral blood mononuclear cells have
been shown to be adsorbed on the CPB circuit where
they become activated to express low levels of TF,
thereby contributing to the overall procoagulant
response.6 A role for the extrinsic pathway in CPB has
also been suggested. In a study by Burman and col-
leagues,5 a sharp rise in markers of thrombin genera-
tion was noted in a patient with factor XII deficiency
who was undergoing CPB, suggesting coagulation acti-
vation apart from the intrinsic system. Additionally,
Chung and colleagues8 have reported enhanced expres-
sion of TF in monocytes isolated from pericardial blood
during CPB, supporting the notion that the surgical
wound itself (and thus the extrinsic system) represents
a critical stimulus to activation.
Taken together, these data suggest that all 3 predom-
inant stimuli contribute to the enormous prothrombotic
stimulus during CPB. We based our studies on the
premise that each of these stimuli contribute distinc-
tively to the activation of coagulation and therefore
may be inhibited in a targeted manner. We propose that
the ideal anticoagulant would selectively block those
stimuli that contribute to intravascular coagulation,
Fig 3. Analysis of thrombin generation in baboons undergo-
ing CPB. Baboons underwent CPB with either IXai (solid
line) or heparin/protamine (dashed line). A, At the indicated
times, blood was withdrawn from a peripheral arterial line for
analysis by ELISA for TAT and prothrombin activation pep-
tide (F1+2). B, Compared with heparin-treated animals, ani-
mals treated with IXai revealed significantly increased levels
of both markers. *P < .05, by ANOVA.
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while allowing those stimuli responsible for extravas-
cular hemostasis to proceed unimpeded.
Heparin, the traditional anticoagulant used in CPB,
blocks both the intrinsic and extrinsic pathways at mul-
tiple sites in the cascade.9-12 In contrast, factor IX occu-
pies a unique position in the coagulation cascade and
therefore may be a perfect target for a more selective
anticoagulant strategy (Fig 1). Blockade of factor IX/IXa
inhibits the progression of the classic intrinsic pathway
by impairing thrombin generation from blood contact
with the bypass circuit. Furthermore, in the setting of
low levels of TF (such as those expressed on activated
monocytes), inhibition of factor IX/IXa will also block
activation of factor X.9-13 However, in the presence of
high concentrations of TF (such as those present in the
surgical wound), inhibition of factor IX will not affect
the direct activation of X that will proceed unimpeded
via the TF–factor VIIa–mediated pathway.16
In this report, we demonstrate that IXai functions as
an effective anticoagulant in primate CPB, maintaining
blood fluidity in the extracorporeal circulation while
preserving hemostasis in the surgical wound. Further-
more, by evaluating the sites and extent of thrombin
generation in this model, these data underscore the sep-
arate contributions of intrinsic and extrinsic stimuli in
the overall procoagulant response to CPB. Signifi-
cantly increased levels of TAT and F1+2 in the peripher-
al plasma of IXai-treated animals on bypass demon-
strate that overall thrombin generation is greater in
baboons treated with IXai compared with those treated
with heparin. We attribute these findings to the relative
preservation of extravascular hemostasis and thrombin
generation in the surgical wound of animals treated
with IXai because there was no evidence of intravascu-
lar thrombosis.
Further, in preliminary studies in an isolated percuta-
neous model of CPB (data not shown), peripheral
thrombin generation (TAT and F1+2) was found to be
Fig 4. Anti-TF IgG or nonimmune (mouse) IgG-stained sections of pericardium (original magnification · 25)
revealed striking TF expression (A) in pericardial macrophages, (B) in the vasculature that pervade pericardial tis-
sue, or (C) in pericardial mesothelial cells; (D) staining of an adjacent section with nonimmune IgG was negative.
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equivalent in IXai- and heparin-treated animals. In ster-
notomy controls without CPB, peripheral thrombin gen-
eration was significantly greater in IXai-treated animals
compared with those treated with heparin. Because
these models isolate the separate contributions of the
surgical wound (sternotomy model) and the CPB circuit
(percutaneous model), these additional preliminary
findings suggest that activation of coagulation within
the bypass circuit may be attributed solely to stimula-
tion of the intrinsic pathway with a contribution from
TF expressed on adherent monocytes. Consequently,
activation in the surgical wound may be separately
attributable to stimulation of the extrinsic pathway.
Moreover, in support of the notion that activation of
the extrinsic pathway occurs uniquely in the surgical
wound, in this study we demonstrated monocyte TF
activity to be different in the intravascular as compared
with the extravascular space in IXai-treated animals.
Retrieval of monocytes in both IXai- and heparin-treat-
ed animals from the intravascular space (peripheral
blood, the arterial filter, and the CPB circuit) revealed
no demonstrable TF activity. In contrast, only in IXai-
treated animals did monocytes isolated from the
extravascular space (pericardial blood) manifest signif-
icantly enhanced TF activity. Such results are consis-
tent with those of Chung and colleagues,8 who demon-
strated similar findings of increased pericardial
monocyte TF activity.8 Interestingly, our data may also
help to explain the more recent findings of Ernofsson
and colleagues,29 who described no TF expression by
circulating peripheral blood mononuclear cells during
CPB.
Complementing these findings of increased TF activ-
ity in the surgical wound, results of our immunohisto-
chemical examination of the pericardium during CPB
demonstrated cellular TF expression. Our findings of
striking TF expression by pericardial mesothelial cells,
and by the vasculature and macrophages that pervade
pericardial tissue, further localize TF to the surgical
wound where its presence may lead to direct activation
of the extrinsic system.30
Although multiple studies have implicated an
inevitable contribution from the intrinsic system during
CPB, our data support additional roles for both activat-
ed monocytes and for the extrinsic system. Thus
despite the complex set of intrinsic/extrinsic interac-
tions that together underlie the coagulopathy of CPB,
targeted selective anticoagulation not only represents a
feasible antithrombic strategy but also unveils an ideal
anticoagulant approach for cardiac surgery. During
CPB, selective anticoagulation with IXai takes advan-
tage of the described distinct procoagulant stimuli and
thereby allows for effective protection against intravas-
cular/low TF-mediated thrombosis, while protecting
surgical hemostasis.
We thank Dr Steven McCormick (New York Eye and Ear
Hospital, New York, NY) for performing scanning electron
microscopy on the arterial filters processed after baboon
CPB.
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Discussion
Dr Eric A. Rose (New York, NY). What happens to the
platelets, if anything, in this milieu?
Dr Spanier. We have looked at sensitive markers of
platelet, first by studies of platelet aggregation, where we
found that there was no evidence of enhanced platelet aggre-
gation in the presence of IXai, whereas there is significantly
enhanced platelet aggregation in the presence of heparin.
Further, in preliminary studies that we have been able to do
recently in an extended primate model of CPB, we found by
looking for surface markers of platelet activation (such as
CD62, P-selectin, and CD41 and 42) that there is no signifi-
cant increase in IXai-treated animals whereas there is a sig-
nificant increase in all of these markers in heparin-treated
animals. Thus we believe there is a relative preservation of
platelet function in the presence of IXai. 
Dr Jack G. Copeland III (Tucson, Ariz). I am worried
about the elevation of intravascular thrombin in this therapy
and the deleterious effects it may have as an inflammatory, a
platelet stimulatory, and a prothrombotic agent. What are
your comments on that?
Dr Spanier. We recently went to Saudi Arabia where we
operated on 88 baboons and were able to do a study that is
more comprehensive than this one. In that study we were able
to isolate the surgical wound, the CPB circuit, and the entire
effect of bypass circuit and surgical wound by doing 3 mod-
els of CPB: a percutaneous model, a model in which we only
did a median sternotomy, and then a routine, standard open
CPB through a median sternotomy. 
In that model what we found (which we were hoping to
find) was that thrombin generation, although elevated in the
open CPB model in the peripheral plasma, was significantly
attenuated to the level of the heparin-treated animals in the
percutaneous model, further supporting our contention that
the stimulus for thrombin generation was in fact in the surgi-
cal wound. In the absence of that surgical wound, that stimu-
lus was taken away. Furthermore, the absence of intravascu-
lar thrombus suggested to us that the markers of peripheral
thrombin generation did not have a significant effect on the
procoagulant milieu. 
Furthermore, you addressed the issue of inflammatory acti-
vation, which is certainly one of the most important in the set-
ting of CPB. By using these 3 separate models, we found that
not only do we have attenuated intravascular thrombus with
IXai, but more important, perhaps, in the presence of IXai as
compared with heparin, we have attenuation of complement,
inflammatory mediators, such as interleukin-6 and inter-
leukin-8 and the described decreases in platelet activation.
Not only do we think that IXai is going to represent a target-
ed anticoagulant approach, but it also suggests the critical
interactions between the proinflammatory and procoagulant
milieu during CPB and further suggests the targeted directed
approach to block both the procoagulant and the proinflam-
matory response to cardiac surgery.
Dr John C. Chen (Orange, Calif). With IXai, do you have
evidence that this is a specific inhibitor for factor IXa? Is this
applicable to human beings? Is IXai that is specific for mon-
keys applicable to the human species?
Dr Spanier. IXai is specific for the inhibition of factor IX
in plasma. We know this by both binding studies. We found
in dose-response studies that, at low doses and at the
antithrombotic dose that we use of IXai (which is about 460
m g/kg), we have specific factor IX inhibition, which we test
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using factor-deficient plasmas. We are able to show that there
is no inhibition of factor XII, XI, or VIII during the proce-
dure, whereas there is specific inhibition of IX. At higher
doses of IXai, though, we do find that there is some inhibition
of the other coagulation factors. 
Regarding the second question that you had about the clin-
ical applicability, we have had the fortunate experience at
Columbia of using Institutional Review Board exemptions in
several patients who had been critically ill and had no real
alternative, to be able to use IXai in the clinical setting.We
have used it in the setting of CPB and in the setting of other
extracorporeal circuits, such as extracorporeal membrane
oxygenation (ECMO). We found in those patients that there is
significant attenuation of thrombin generation in the periph-
eral plasma, and we were able to keep those circuits that I
have just described open in the setting of IXai with no
demonstrable adverse effects to this treatment. Furthermore,
what we found in these patients is that we were able to stop
the bleeding extravascularly in their wounds and to anticoag-
ulate their circuits.
Dr Ahmad Rajaii Khorasan (Neptune, NJ). Do you think
this agent will block the stimulatory effect of heparin on
platelets?
Dr Spanier. We have actually done the studies using both
heparin and IXai in the same platelet aggregometer, and we
found that IXai does seem to attenuate some of the heparin
effects on platelets. We are not exactly sure of the mechanism
of this yet, unless IXai does truly have a protective effect on
platelets. What we think is more likely is that there are critical
interactions between the ways that the inflammatory system
(as I described) and the coagulation system are activated, and
platelets probably play an important role there. IX may be one
of the markers, one of the kind of entrances to the critical inter-
actions between the inflammatory and the coagulant pathways.
